Coherus Oncology, Inc. (NASDAQ: CHRS), a fully integrated commercial-stage oncology company, disclosed on February 12, 2026, that it intends to move forward with an underwritten public offering of common stock. This capital raise represents a strategic move to strengthen the company's commercial